Pathophysiology	O
,	O
treatment	B:C0087111
and	O
prevention	O
of	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
.	O

Pathophysiology	O
,	O
treatment	O
and	O
prevention	B:C0199176
of	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
.	O

Pathophysiology	O
,	O
treatment	O
and	O
prevention	O
of	O
ovarian	B:C0085083
hyperstimulation	I:C0085083
syndrome	I:C0085083
.	O

Severe	O
ovarian	B:C0085083
hyperstimulation	I:C0085083
syndrome	I:C0085083
(	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
)	O
is	O
an	O
iatrogenic	O
condition	O
that	O
affects	O
1	O
%	O
of	O
women	O
that	O
undergo	O
treatment	O
with	O
assisted	O
reproductive	I:C0872104
technology	I:C0872104
.	O

Severe	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
(	O
ovarian	B:C0085083
hyperstimulation	I:C0085083
syndrome	I:C0085083
)	O
is	O
an	O
iatrogenic	O
condition	O
that	O
affects	O
1	O
%	O
of	O
women	O
that	O
undergo	O
treatment	O
with	O
assisted	O
reproductive	I:C0872104
technology	I:C0872104
.	O

Severe	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
(	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
)	O
is	O
an	O
iatrogenic	O
condition	O
that	O
affects	O
1	O
%	O
of	O
women	B:C0043210
that	O
undergo	O
treatment	O
with	O
assisted	O
reproductive	I:C0872104
technology	I:C0872104
.	O

Severe	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
(	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
)	O
is	O
an	O
iatrogenic	O
condition	O
that	O
affects	O
1	O
%	O
of	O
women	O
that	O
undergo	O
treatment	B:C0087111
with	O
assisted	O
reproductive	I:C0872104
technology	I:C0872104
.	O

Severe	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
(	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
)	O
is	O
an	O
iatrogenic	O
condition	O
that	O
affects	O
1	O
%	O
of	O
women	O
that	O
undergo	O
treatment	O
with	O
assisted	B:C0872104
reproductive	I:C0872104
technology	I:C0872104
.	O

The	O
review	B:C0282443
aims	O
to	O
summarize	O
recent	O
evidence	O
on	O
pathophysiology	O
,	O
treatment	O
,	O
and	O
prevention	O
of	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
.	O

The	O
review	O
aims	O
to	O
summarize	B:C1706244
recent	O
evidence	O
on	O
pathophysiology	O
,	O
treatment	O
,	O
and	O
prevention	O
of	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
.	O

The	O
review	O
aims	O
to	O
summarize	O
recent	O
evidence	O
on	O
pathophysiology	O
,	O
treatment	B:C0087111
,	O
and	O
prevention	O
of	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
.	O

The	O
review	O
aims	O
to	O
summarize	O
recent	O
evidence	O
on	O
pathophysiology	O
,	O
treatment	O
,	O
and	O
prevention	B:C0199176
of	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
.	O

The	O
review	O
aims	O
to	O
summarize	O
recent	O
evidence	O
on	O
pathophysiology	O
,	O
treatment	O
,	O
and	O
prevention	O
of	O
ovarian	B:C0085083
hyperstimulation	I:C0085083
syndrome	I:C0085083
.	O

The	O
pathophysiology	O
is	O
still	O
not	O
completely	O
understood	B:C0162340
;	O
however	O
,	O
vascular	O
endothelial	I:C0078058
growth	I:C0078058
factor	I:C0078058
is	O
likely	O
to	O
be	O
an	O
important	O
mediator	O
.	O

The	O
pathophysiology	O
is	O
still	O
not	O
completely	O
understood	O
;	O
however	O
,	O
vascular	B:C0078058
endothelial	I:C0078058
growth	I:C0078058
factor	I:C0078058
is	O
likely	O
to	O
be	O
an	O
important	O
mediator	O
.	O

Human	B:C1141639
chorionic	I:C1141639
gonadotropin	I:C1141639
was	O
previously	O
thought	O
to	O
be	O
necessary	O
for	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
to	O
occur	O
;	O
however	O
,	O
recent	O
case	I:C0007320
reports	I:C0007320
have	O
proven	O
otherwise	O
.	O

Human	O
chorionic	I:C1141639
gonadotropin	I:C1141639
was	O
previously	O
thought	B:C0039869
to	O
be	O
necessary	O
for	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
to	O
occur	O
;	O
however	O
,	O
recent	O
case	I:C0007320
reports	I:C0007320
have	O
proven	O
otherwise	O
.	O

Human	O
chorionic	I:C1141639
gonadotropin	I:C1141639
was	O
previously	O
thought	O
to	O
be	O
necessary	O
for	O
ovarian	B:C0085083
hyperstimulation	I:C0085083
syndrome	I:C0085083
to	O
occur	O
;	O
however	O
,	O
recent	O
case	I:C0007320
reports	I:C0007320
have	O
proven	O
otherwise	O
.	O

Human	O
chorionic	I:C1141639
gonadotropin	I:C1141639
was	O
previously	O
thought	O
to	O
be	O
necessary	O
for	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
to	O
occur	O
;	O
however	O
,	O
recent	B:C0007320
case	I:C0007320
reports	I:C0007320
have	O
proven	O
otherwise	O
.	O

The	O
contribution	O
of	O
an	O
attenuated	O
anti-Mullerian	B:C0066928
hormone	I:C0066928
signalling	O
pathway	I:C0037083
and	O
CD11c	O
+	O
HLA	O
-	I:C0019764
DR	I:C0019764
+	O
dendritic	O
cells	I:C0011306
and	O
associated	O
interleukins	O
has	O
been	O
explored	O
recently	O
as	O
contributors	O
to	O
pathogenesis	O
.	O

The	O
contribution	O
of	O
an	O
attenuated	O
anti-Mullerian	O
hormone	I:C0066928
signalling	B:C0037083
pathway	I:C0037083
and	O
CD11c	O
+	O
HLA	O
-	I:C0019764
DR	I:C0019764
+	O
dendritic	O
cells	I:C0011306
and	O
associated	O
interleukins	O
has	O
been	O
explored	O
recently	O
as	O
contributors	O
to	O
pathogenesis	O
.	O

The	O
contribution	O
of	O
an	O
attenuated	O
anti-Mullerian	O
hormone	I:C0066928
signalling	O
pathway	I:C0037083
and	O
CD11c	B:C0023395
+	O
HLA	O
-	I:C0019764
DR	I:C0019764
+	O
dendritic	O
cells	I:C0011306
and	O
associated	O
interleukins	O
has	O
been	O
explored	O
recently	O
as	O
contributors	O
to	O
pathogenesis	O
.	O

The	O
contribution	O
of	O
an	O
attenuated	O
anti-Mullerian	O
hormone	I:C0066928
signalling	O
pathway	I:C0037083
and	O
CD11c	O
+	O
HLA	B:C0019764
-	I:C0019764
DR	I:C0019764
+	O
dendritic	O
cells	I:C0011306
and	O
associated	O
interleukins	O
has	O
been	O
explored	O
recently	O
as	O
contributors	O
to	O
pathogenesis	O
.	O

The	O
contribution	O
of	O
an	O
attenuated	O
anti-Mullerian	O
hormone	I:C0066928
signalling	O
pathway	I:C0037083
and	O
CD11c	O
+	O
HLA	O
-	I:C0019764
DR	I:C0019764
+	O
dendritic	B:C0011306
cells	I:C0011306
and	O
associated	O
interleukins	O
has	O
been	O
explored	O
recently	O
as	O
contributors	O
to	O
pathogenesis	O
.	O

The	O
contribution	O
of	O
an	O
attenuated	O
anti-Mullerian	O
hormone	I:C0066928
signalling	O
pathway	I:C0037083
and	O
CD11c	O
+	O
HLA	O
-	I:C0019764
DR	I:C0019764
+	O
dendritic	O
cells	I:C0011306
and	O
associated	O
interleukins	B:C0021764
has	O
been	O
explored	O
recently	O
as	O
contributors	O
to	O
pathogenesis	O
.	O

The	O
contribution	O
of	O
an	O
attenuated	O
anti-Mullerian	O
hormone	I:C0066928
signalling	O
pathway	I:C0037083
and	O
CD11c	O
+	O
HLA	O
-	I:C0019764
DR	I:C0019764
+	O
dendritic	O
cells	I:C0011306
and	O
associated	O
interleukins	O
has	O
been	O
explored	O
recently	O
as	O
contributors	O
to	O
pathogenesis	B:C0699748
.	O

Treatment	B:C0087111
is	O
largely	O
supportive	O
and	O
is	O
based	O
mainly	O
on	O
consensus	O
statements	O
rather	O
than	O
evidence	O
.	O

Treatment	O
is	O
largely	O
supportive	B:C0344211
and	O
is	O
based	O
mainly	O
on	O
consensus	O
statements	O
rather	O
than	O
evidence	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
prevent	O
this	O
condition	O
by	O
identifying	B:C1269815
women	O
at	O
risk	O
,	O
allowing	O
the	O
clinician	O
to	O
implement	O
preventive	O
strategies	O
,	O
including	O
the	O
use	O
of	O
GnRH	O
antagonist	I:C1268855
cycles	O
with	O
agonist	O
triggers	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
prevent	O
this	O
condition	O
by	O
identifying	O
women	B:C0043210
at	O
risk	O
,	O
allowing	O
the	O
clinician	O
to	O
implement	O
preventive	O
strategies	O
,	O
including	O
the	O
use	O
of	O
GnRH	O
antagonist	I:C1268855
cycles	O
with	O
agonist	O
triggers	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
prevent	O
this	O
condition	O
by	O
identifying	O
women	O
at	O
risk	O
,	O
allowing	O
the	O
clinician	B:C0871685
to	O
implement	O
preventive	O
strategies	O
,	O
including	O
the	O
use	O
of	O
GnRH	O
antagonist	I:C1268855
cycles	O
with	O
agonist	O
triggers	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
prevent	O
this	O
condition	O
by	O
identifying	O
women	O
at	O
risk	O
,	O
allowing	O
the	O
clinician	O
to	O
implement	O
preventive	O
strategies	O
,	O
including	O
the	O
use	O
of	O
GnRH	B:C1268855
antagonist	I:C1268855
cycles	O
with	O
agonist	O
triggers	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
prevent	O
this	O
condition	O
by	O
identifying	O
women	O
at	O
risk	O
,	O
allowing	O
the	O
clinician	O
to	O
implement	O
preventive	O
strategies	O
,	O
including	O
the	O
use	O
of	O
GnRH	O
antagonist	I:C1268855
cycles	O
with	O
agonist	B:C2987634
triggers	O
.	O

More	O
research	B:C0035168
is	O
required	O
to	O
elucidate	O
the	O
pathophysiology	O
behind	O
the	O
condition	O
.	O

Clinicians	B:C0871685
should	O
employ	O
strategies	O
to	O
prevent	O
ovarian	O
hyperstimulation	I:C0085083
syndrome	I:C0085083
.	O

Clinicians	O
should	O
employ	O
strategies	O
to	O
prevent	O
ovarian	B:C0085083
hyperstimulation	I:C0085083
syndrome	I:C0085083
.	O

